154
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Alashanoids K-M, bioactive eremophilane sesquiterpenoids from Syringa pinnatifolia

, , , , , , , & show all
Pages 1161-1169 | Received 12 Sep 2019, Accepted 11 Nov 2019, Published online: 25 Nov 2019
 

Abstract

Three new eremophilane-type sesquiterpenoids, alashanoids K–M (13), and one known analogue (4) were isolated from the peeled stems of Syringa pinnatifolia. All the compounds were isolated from the genus Syringa for the first time. Structures of these compounds were established using 1D and 2D NMR and MS data. The absolute configurations were determined by experimental and calculated electronic circular dichroism analysis, a modification of Mosher’s method, and X-ray diffraction. Compounds 2 and 3 inhibited NO production in LPS-induced RAW264.7 macrophage cells with IC50 values of 14.23 and 12.20 μM, respectively, and showed cytotoxic activities against HepG2 cells with the IC50 values of 34.41 and 40.86 μM, respectively.

Graphical Abstract

Disclosure statement

No potential confliction of interest was claimed.

Additional information

Funding

This research was funded by the National Natural Science Foundation of China, grant numbers 81473426 and 81774001, and China Key Project at Central Government Level: the ability establishment of sustainable use for valuable Chinese medicine resources (2060302).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.